Corindus Vascular Robotics Inc

Corindus Vascular Robotics — Investor Presentation (August 2015)

27 slides from Corindus Vascular Robotics's investor presentation, Aug 25, 2015

  1. Slide 1: Precision Vascular Robotics

    Exhibit 99.1 Precision Vascular Robotics Corindus Vascular Robotics (CVRS) Overview August 2015

  2. Slide 2: Forward Looking Statements

    FORWARD LOOKING STATEMENTS THIS PRESENTATION CONTAINS “FORWARD-LOOKING STATEMENTS” (AS SUCH TERM IS DEFINED IN SECTION 27A OF THE SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND INFORMATION RELATING TO THE COMPANY, THAT ARE BASED ON THE CUR

  3. Slide 3: Corindus Growth Platform

    Corindus Growth Platform Interventional robotics leadership • CorPath® System: Only FDA cleared Protection robotic-assisted percutaneous coronary Staff Safety intervention (“PCI”) system • PCI is a high volume, (~933k), US medical robotics procedure opportunity; long growth runway New Standard • Cat

  4. Slide 4: Experienced Leadership Team

    Experienced Leadership Team Experience in the cardiovascular field Management Strong Investor Base David Handler President & CEO David Long VP Finance, CFO 4

  5. Slide 5: Cath Lab Procedure Innovation

    Cath Lab Procedure Innovation CorPath Robotic-assisted PCI PCI procedure remains largely unchanged since introduction • Innovation historically focused on stents and delivery systems • Traditional PCI not optimized to required levels of complexity, dexterity and precision The CorPath System offers:

  6. Slide 6: Vascular Robotics Market

    Vascular Robotics Market CorPath platform potential to expand vascular indications Coronary Peripheral Neuro Structural Corindus IP and Technology 6

  7. Slide 7: Corindus Market Opportunity

    Corindus Market Opportunity 2 $4.5B FY2018 market estimate Total Revenue New Systems Consumables Service Opportunity ($, mm) ($, mm) ($, mm) ($, mm) $244 $513 $122 $879 US -PCI $218 $862 $109 $1,190 subtotal $462 $1,375 $231 $2,068 $256 $757 $128 $1,141 OUS -PCI $229 $1,006 $115 $1,350 subtotal $485

  8. Slide 8: Product Overview

    Product Overview Corindus Vascular Robotics

  9. Slide 9: CorPath Robotic-Assisted PCI System

    CorPath Robotic-Assisted PCI System 9

  10. Slide 10: CorPath Robotic-Assisted PCI System

    CorPath Robotic-Assisted PCI System CorPath Installation • The CorPath system fits in any cath lab and is compatible with all fluoroscopy systems; Philips, GE, Siemens, Toshiba. • No construction is required. Several electronic cables are used to connect the bedside with the cockpit for robotics and

  11. Slide 11: Today's Cath Lab Challenges

    Today’s Cath Lab Challenges Staff Safety and Health is at Risk • The cath lab is a dangerous environment for workers » Radiation exposure cancer and cataract risk » Ergonomic Strain orthopedic injury and chronic pain Procedure Outcomes Not Optimal • Difficulty viewing angiography standing at bedside

  12. Slide 12: Safety in a Hazardous Environment

    Safety in a Hazardous Environment Reduce radiation exposure, orthopedic injury and pain Traditional PCI CorPath Robotic PCI • Lab ergonomics create awkward working • Radiation shielded work station reduces positions exposure from head to toe • Improved ergonomics - work from a seated • Lead protecti

  13. Slide 13: Escalating Awareness of Risks

    Escalating Awareness of Risks Accelerating publication frequency CCI, April 2015 ORSIF, February 2015 JACC Interventions, April 2015 JACC, March 2015 CCI, February 2015 13

  14. Slide 14: Occupational Risks in the Cath Lab

    Occupational Risks in the Cath Lab Radiation and orthopedic injury • Brain tumors – Reported brain tumors are predominately left-side amongst 1 interventionalists • Orthopedic injuries2,4 – 60% incidence of spine issues after 21 years in practice – 42% incidence of spine problems - General populatio

  15. Slide 15: Traditional PCI vs. CorPath Robotic PCI

    Traditional PCI vs. CorPath ® Robotic PCI Enhanced procedure may improve outcomes, economics and safety Traditional PCI CorPath PCI steps Robotic PCI Struggle to see Assess Close proximity angiography Anatomy ergonomic visualization Trial & error, wire Precise ‘Point & Shoot’ Navigate spinning predi

  16. Slide 16: Precision Matters in PCI

    Precision Matters in PCI How does precision impact patients? • Inaccurate lesion assessment – ~65% physicians select stent length based on visual 1 estimation alone 2 – 51% of physicians underestimated lesion length – Inaccurate estimate lead to sub-optimal PCI procedure and can cause LGM • Longitud

  17. Slide 17: PRECISE vs. Historical Data

    PRECISE vs. Historical Data Compares CorPath robotic vs. historical PCI procedure Nikolsky et al, 2007 [1] Fluoro time 23 min PRECISE study [2] (N=7,242 pts) (N=164 pts) Age 63.9 ±11.8 64.1±10.0 Lesionlength (mm) 12.8 ± 6.7 13.4± 4.0 Numberof Stents 1.20 ± 0.83 1.1 ± 0.34 Fluoroscopy time(min) 12.7

  18. Slide 18: Clinical Evidence – Precision Matters

    Clinical Evidence – Precision Matters Peer reviewed publication highlights Continued Investment in Clinical Data • Post PRECISE sub-analysis • PRECISION registry post market data collection and analysis vs. manual procedures • Concurrent studies to prove procedure benefits of CorPath robotic precisi

  19. Slide 19: Commercial Strategy

    Commercial Strategy Corindus Vascular Robotics

  20. Slide 20: Sales Strategy

    Sales Strategy Dedicated system and cassette sales teams System Sales Team • Experienced medical technology sales professionals – System ‘hunters’ • Sales process initiates with Interventional Cardiologist champion, then progresses through hospital administration • Leveraging both capital purchase a

  21. Slide 21: Intellectual Property

    Intellectual Property Corindus Vascular Robotics

  22. Slide 22: Intellectual Property Overview

    Intellectual Property Overview Expanding on a strong foundation Continuous “Ring-fencing” all vascular robotics applications: • 38 issued global patents • 51 patents pending: broad application coverage • Continuously building IP portfolio • Pursuing the vascular space broadly Corindus IP covers remo

  23. Slide 23: Financials

    | ° Financials Corindus Vascular Robotics

  24. Slide 24: Key Financial Information

    Key Financial Information Key Metrics* Cash, Cash Equivalents and Marketable Securities $58.9 million Debt** $10.0 million Basic Shares Outstanding 118,533,157 Warrants Outstanding 5,207,379 Stock Options Outstanding 8,597,961 * As of June 30, 2015 ** Outstanding principal balance 24

  25. Slide 25: Summary

    Summary Corindus Vascular Robotics

  26. Slide 26: Corindus Growth Platform

    Corindus Growth Platform Interventional robotics leadership • Cath Lab occupational hazards concerns and awareness are growing • PCI is a very large volume medical robotics procedure opportunity; long growth runway • Growing CorPath installed base for commercial foundation and regional show sites •

  27. Slide 27: Precision Vascular Robotics

    Precision Vascular Robotics The New Standard of Care in Vascular Procedures About Corindus Vascular Robotics Corindus Vascular Robotics is a global technology leader in robotic-assisted percutaneous coronary interventions. The company’s CorPath System is the first medical device that offers interven

Corindus Vascular Robotics — Investor Presentation (August 2015) on 6ix